Evopoint Completes $700 Million Series E Financing to Accelerate R&D and Commercialization of Innovative Drugs

Inthe upcoming Year of the Loong, prosperity is anticipated, as the Dragonspreads its wings. Evopoint Biosesciences Co., Ltd. (hereinafter referred to asEvopoint) successfully completed the Series E funding round with RMB 700million. This round of financing was jointly led by one of the leading venturecapital firms in China and Guoxin Investment Group, along with theparticipation of a number of well-known institutions such as Jinan IndustrialDevelopment Investment Group, TH Capital, Yuekai Capital, Chenhai Capital,Pudong Venture Capital, and Zhuopu Capital, with the continued support of theold shareholders of Loyal Valley Capital, as well as with Start Point Advisors actingas the exclusive financial advisor for this round of financing.

Thefunds raised in this round will mainly be used to promote the domestic andinternational clinical trials of multiple company pipelines, improve the threemajor technology platforms of independent innovation of targeted therapy,anti-infection and PROTAC, accelerate the operation of the production base aswell as the construction of the commercialization team, and push for an earlyproduct launch to benefit a vast population of patients.

Establishedin 2017, Evopoint Biosesciences is an innovative biopharmaceutical company withextraordinary R&D and commercialization capabilities. Leveragingproprietary discovery platforms for targeted therapy, anti-infective andPROTAC, Evopoint has developed a robust pipeline of clinical assets featuringaβ-lactamase inhibitor, an EZH2 inhibitor, an hURAT1 inhibitor, next-generationADCs, and many more preclinical programs in focused disease areas includingoncology, infectious and metabolic diseases. The company has establishedmultiple out-licensing partnerships with domestic and global pharma companiesto co-develop its assets for global markets. Potential value of thesepartnerships surpasses billion dollars. Since its inception, Evopoint iscommitted to improving human health by providing innovative pharmaceuticalsolutions to address greatest unmet medical needs globally.

Amongthese, XNW4107 is a new generation of β-lactamase-based broad-spectrumanti-drug-resistant bacterial drug independently developed by Evopoint, withstrong antibacterial efficacy against the ever-increasing cases of carbapenem-resistantbacterial infections, such as the Carbapenem-Resistant Acinetobacter baumannii(CRAB), Pseudomonas aeruginosa (CRPA), and Enterobacteriaceae (CRE). This drugis currently undergoing critical, global multicenter Phase III clinical study.

XNW3009,a new generation of uric acid lowering drug, has entered Phase III clinicaltrials, having completed two randomized, double-blind controlled trials. Inthese two trials, XNW3009's uric acid lowering effect was respectively shown tobe far superior to those of the control groups – benzbromarone and febuxostat,the two drugs with the largest prescription volumes and the highest sales inthe current Chinese market.

Inthe field of oncology, XNW5004, a new generation EZH2 inhibitor, has shownexcellent anti-tumor efficacy in hematoma, prostate cancer and otherindications, and is currently in Phase II clinical trials. It has entered intoa cooperation with MSD to carry out a clinical trial of co-administration with Keytruda.The new generation ADC drugs XNW27 and XNW28 are in Phase I clinical trials andhave demonstrated significantly stronger efficacy and higher therapeutic windowpotential than competitors with the same target.

Relyingon its stellar product data and external licensing capabilities, Evopoint hasentered into a number of external licensing cooperation with well-knowncompanies both domestically and abroad, amounting to billions of USD in total, andis one of the companies that have reached the largest number of “License out”in the domestic biopharmaceutical field.

Sinceits establishment, the company has been highly recognized by investors, and hasintroduced domestic and foreign first-tier investment institutions, including LoyalValley Capital, GIC, Oceanpine Capital, and CICC Capital. Meanwhile, thecompany has also received strong support from state-owned institutions such asGuoxin Investment Group, Jinan Industrial Development Investment Group, YuekaiCapital, Pudong Venture Capital, Guofa Venture Capital, Zhuopu Capital, and ABCInternational, and has received a cumulative total of more than RMB 2 billion infinancing.

Evopointwill continue to work with determined confidence, maintaining the enthusiasmand motivation that will assemble in to a collective effort to create a betterfuture.

Investmentinstitutions of Series E funding round stated: I am pleased to participate inthe Series E funding round of Evopoint. Evopoint is an innovative drug company thatfocuses on significant unmet clinical needs. Since the last round of funding,the company has demonstrated impressive execution, and several products areabout to enter the market validation stage. The company has completed thetransition from a “product-based” company to a “platform-based” company, andhas built several leading technology platforms. Based on the efficient R&Dsystem and its excellent capabilities, the company is actively going overseasand has completed the “License out” of many overseas pipelines’ interests. Weare firmly optimistic about the founding team and product pipeline of Evopoint,and hope that this round of funding can help the products enter the market and benefita vast population of patients.

AboutGuoxin Investment

Foundedin 2000 with a registered capital of RMB 4 billion, Guoxin Investment is awholly-owned subsidiary of Shanghai State-owned Assets Management Co. GXIaccumulated many years of experience in equity investment, with strong projectscreening, investment and management capabilities, and has successfullyinvested in a number of well-known domestic biopharmaceutical and medicaldevice companies, such as Tiger Pharmaceuticals, Aier Ophthalmology, DongchengPharmaceuticals, Lianyin Medical and Lepu Medical, etc. GXI will always adhereto the principle of “discovering value and creating value, and growing togetherwith outstanding enterprises”. Guoxin Investment will always adhere to thebusiness philosophy of “discovering value, creating value, and growing withoutstanding enterprises”, and will continue to play an important role in theimplementation of SIG's strategic function of empowering the real economy withfinancial capital and supporting the construction of Shanghai's science andinnovation center.

AboutJinan Industrial Development Investment Group

Foundedin 2016, Jinan Industrial Development Investment Group Co., Ltd. is astate-controlled group company approved by the Jinan Municipal Government,integrating industrial investment, park development, industrial operation andother businesses. Under the leadership of the municipal party committee and themunicipal government, and with the mission of “developing the city throughindustry and repaying the country through development”, the group focuses onstrategic emerging industries such as new-generation information technology,new energy, biomedicine, high-end equipment manufacturing, etc., and has set upthree major fund platforms, namely, the Industrial Development Fund, theEconomic Development Fund and the Science and Technology Venture Capital Fund,as well as supporting the setting up of more than 50 parent-subsidiary funds,which have a total investment scale of nearly RMB 50 billion yuan. The totalsize of the funds is nearly RMB 50 billion, with nearly 200 investmentprojects. The construction and operation of industrial parks has exceeded 10million square meters, introduced more than 1,500 enterprises, and driven theemployment of more than 15,000 people, providing parks and carriers for thecultivation of industrial clusters.

AboutLoyal Valley Capital

Withthe investment values of “Long-term, Focused and Altruistic”, Loyal ValleyCapital

iscommitted to establishing the best investment research team and post-investmentmanagement team in China, covering the three major fields of new science andtechnology, new medical care and new consumption, and accompanying outstandingentrepreneurs through in-depth industrial research and post-investmentproactive empowerment, to build great companies that represent the direction ofChina's future growth and create value for the society. We will accompanyoutstanding entrepreneurs through in-depth industrial research andpost-investment active empowerment, and work together to build greatenterprises that represent the future growth of China's economy and createvalsue for society. Since its inception in 2015, CZG has invested in a number ofoutstanding enterprises that represent the future development direction ofChina's economy, including SUPCON, UNISOC, CALB Tech, Avary Holding, RIGOLTechnologies, O-Net Technology, Bayi Space, Junshi Biolosciences, InnocarePharma, AkesoBio, RemeGen Biosesciences, CARsgen, ObiO Technology, Allist,BiliBili, ByteDance, POP MART, NetEase Music, and more than 100 outstandingheadline companies.

AboutTH Investment

Foundedin 2007, TH Investment has a series of 20 sub-funds investing in VC, PE,industry funds, M&A funds, overseas funds and general aviation at differentstages and in different specialized fields, with a management scale of over 10billion RMB, and is committed to becoming the most outstanding private equityinvestment institution in China. The fund focuses on investing in leadingcompanies in niche industries, with emphasis on advanced manufacturing andhigh-end equipment, new-generation information technology, carbon neutrality,biotechnology and other fast-growing industries.

AboutYuekai Capital

YuekaiCapital was founded in 2016, since its inception, has set up 12 activelymanaged funds, with a management scale of nearly 6 billion yuan, investmentincluding Avatr, Kyland, Tofflon, SVOLT, Guangzhou Luxvisions, SinoHyKey, TONGYUAUTOMOTIVE and other projects, 2021 returned to Guangzhou Development Zone ofHuangpu District, Guangzhou City, Guangzhou City, since the return to theregion, relying on the regional advantage of industrial resources, and hassuccessfully realized more than 10 projects of investment.

AboutPudong Venture Capital

ShanghaiPudong Innovation Investment Development (Group) Co., Ltd. is a registeredcapital of 10 billion yuan, which is funded by the State-owned AssetsSupervision and Administration Commission of Pudong New Area. It focuses on“fostering scientific and technological innovation and promoting thedevelopment of emerging industries”, and realizes six major business synergies,namely “angel investment, industrial investment, strategic investment, fundinvestment, post-investment management, and industrial research”. It realizesthe synergistic linkage of six major businesses, and builds an investmentsystem that covers the whole life cycle of science and innovation enterprises.The company will also organize the capital chain around the innovation chain,guide more funds, projects, talents and technologies to gather in Pudong, andempower science and technology enterprises, so that “good ideas do not lackfunds, and good enterprises do not lack capital”. Pudong Venture Capitalfocuses on the wind vane of industry development and future industrialexplosion points, invests early and invests small, and focuses on strategicleading enterprises, high-level chain enterprises and major functionalplatforms, invests large and invests strong, injects new vitality intoindustrial development, creates new value, and boosts regional development."Small enterprises will cover the sky and large enterprises stands firm onthe ground.

AboutZhuopu Capital

Foundedin 2018, Suzhou Zhuopu Investment Fund Management Co., Ltd. is a wholly-ownedsubsidiary set up by Suzhou Asset Management Co. Ltd. with a long-term focus onnew-generation information technology, aerospace, semiconductor, biomedicine,artificial intelligence and other fields, with a management scale of over 2billion yuan. Zhuopu Capital actively manages a number of direct investmentfunds such as Zhuopu No. 1 Fund, Gusu Talent II Fund, Zhangjiagang Talent No. 1Fund, Zhuopu Yong Win Fund, Zhuo Yun Qi Sheng Fund, etc., focusing on the fourmajor leading industries in Suzhou, namely, electronic information, high-endequipment, advanced materials and new energy.

AboutStart Point Advisors

StartPoint Advisors is committed to building a first-class new-generation healthcareinvestment bank in China. Founded in 2020, Start Point Advisors isheadquartered in Beijing and Shanghai, with a team of experienced professionalsfrom well-known institutions in the industry. Over the past 4 years, the firmhas covered all mainstream segments and financing stages in the industry. StartPoint Advisors is also one of the few institutions in China with successfulexperience in private equity financing, M&A, BD and exit transactions.

AboutEvopoint

Print this page Close window